Skip to Content

Rilpivirine Dosage

Applies to the following strengths: 25 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

25 mg orally once a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral therapy-naive patients with plasma HIV-1 RNA up to 100,000 copies/mL at the start of therapy

Usual Pediatric Dose for HIV Infection

12 years or older, weighing at least 35 kg: 25 mg orally once a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral therapy-naive patients with plasma HIV-1 RNA up to 100,000 copies/mL at the start of therapy

Renal Dose Adjustments

Mild or moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction, ESRD: Caution and increased monitoring for side effects recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Dose Adjustments

If used with rifabutin: Increase dose to 50 mg orally once a day.
-When rifabutin is stopped: Decrease dose to 25 mg orally once a day.

Precautions

CONTRAINDICATIONS:
-Coadministration with drugs that may significantly decrease rilpivirine plasma levels due to CYP450 3A enzyme induction or gastric pH increase
-Coadministration with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, proton pump inhibitors (e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (more than a single dose), St. John's wort

Safety and efficacy have not been established in patients younger than 12 years or weighing less than 35 kg.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:
-This drug is highly bound to plasma proteins; significant removal via hemodialysis or peritoneal dialysis is unlikely.

Other Comments

Administration advice:
-Use in combination with other antiretroviral drugs.
-Administer with a meal; a protein drink alone does not replace a meal.
-Administer antacids (e.g., aluminum/magnesium hydroxide, calcium carbonate) at least 2 hours before or at least 4 hours after this drug; administer H2-receptor antagonists at least 12 hours before or at least 4 hours after this drug.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
-Store in original bottle to protect from light.

General:
-Limitations of use: More patients starting this drug with HIV-1 RNA greater than 100,000 copies/mL had virologic failure (HIV-1 RNA at least 50 copies/mL) compared to those with HIV-1 RNA up to 100,000 copies/mL.
-No dose adjustment is needed for pregnant patients already on a stable regimen with this drug before pregnancy who are virologically suppressed (HIV-1 RNA less than 50 copies/mL); since lower drug exposures were observed during pregnancy, viral load should be monitored closely.

Monitoring:
-General: Viral load in pregnant patients
-Hepatic: Liver function tests (before and during therapy) and for hepatotoxicity (during therapy) in patients with underlying hepatic disease or marked baseline transaminase elevations; liver enzymes in patients with no preexisting hepatic dysfunction or other risk factors

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).
-Contact healthcare provider at once if rash develops; stop this drug immediately and seek medical care if rash develops with fever, blisters, mucosal involvement, eye inflammation (conjunctivitis), severe allergic reaction (causing swelling of the face/eyes/lips/mouth/tongue/throat, which may lead to difficulty swallowing/breathing), and/or any signs/symptoms of liver problems.
-Seek medical evaluation at once if depressive symptoms develop.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide